The Global Neurodiagnostics Market is Estimated
to Witness High Growth Owing to Technological 

Neurodiagnostics refers to the
diagnostic testing performed to help diagnose neurological disorders and
diseases related to the central and peripheral nervous systems. These tests aid
in evaluating the neurological functioning, neuroanatomical structure, and
identifying injuries or defects in the nervous system. Neurodiagnostics
includes imaging tests such as computed tomography (CT) scans, magnetic
resonance imaging (MRI), electroencephalography (EEG), and lumbar puncture.
Advancements in imaging technologies and identification of new biomarkers have
improved the detection of neurological conditions.



The Global Neurodiagnostics Market is
estimated to be valued at US$ 8.66 Bn in 2024 and is expected to exhibit a CAGR
of 8.1% over the forecast period 2024 To 2031.

Rising geriatric population and the
subsequent increase in neurological disorders, technological advancements in
diagnostic imaging techniques, and growing awareness about early disease
diagnosis are fueling market growth.



Key Takeaways

Key players operating in the Neurodiagnostics Market are Koninklijke Philips
N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings
Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon
Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus
Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro,
NEUROLITE AG, and Atlantic Health System.



Key Neurodiagnostics
Market Trends need for non-invasive diagnostic techniques, untapped
potential in emerging economies, and growing demand for integrated diagnostic
platforms. Advancing technologies in neuroimaging such as high-resolution MRI,
multi-parametric MRI, magnetic resonance spectroscopy, and amyloid and tau
positron emission tomography (PET) have improved diagnostic accuracy.



Market drivers:

The growing geriatric population is the primary driver for the neurodiagnostics
market. The risk of neurological disorders substantially increases with age. As
per the United Nations, the world’s population aged 60 years and above is
expected to double from 12% to 22% between 2015 and 2050. Additionally, rising
incidence of neurological diseases such as Alzheimer's, Parkinson's, epilepsy,
and stroke is another major factor fueling the need for early diagnosis using neurodiagnostic
tests. According to the World Health Organization, 60 million people suffer
from epilepsy worldwide. Neurological conditions accounted for over 10% of the
global disease burden in 2016. Hence, large patient pool and growing incidence
of target diseases will continue to drive the neurodiagnostics market.

Challenges in Neurodiagnostics Market

The Neurodiagnostics
Market Size And Trends is currently facing various challenges such as
high costs involved in product development and failure in meeting exact patient
diagnosis requirements and needs. The market also faces challenges related to
lack of skilled healthcare professionals and appropriate infrastructure for
treatment and diagnosis of neurological disorders.

Get
More Insights On, Neurodiagnostics
Market